

Q3

2008 Q3 INVESTOR FACT SHEET

A world of difference



MDS is a global life sciences company that provides market-leading products and services that our customers need for the development of drugs and diagnosis and treatment of disease. We are a leading global provider of analytical instruments, medical isotopes for molecular imaging, radiotherapeutics and medical devices and pharmaceutical contract research.

globalization



A different world.

MDS is more global than ever, with expanding opportunities in the world's most rapidly growing markets.

innovation



Doing things differently.

Driving innovation.

We are leveraging our strength and building a culture of innovation excellence.

operational excellence




Building world-class operations.

We have strengthened our leadership team around the world and we are stronger, leaner and more competitive.

MDS Inc. TSX: MDS NYSE: MDZ

A world of opportunity



- > In MDS's life sciences business, 95% of revenues come from global markets. MDS has over 5,500 highly skilled employees, operating in 29 countries, and our products and services are distributed to over 82 countries.

■ MDS Global Presence

Q3

2008 Q3 INVESTOR FACT SHEET


F 2008 Q3 Highlights

- > MDS delivered sequential improvement in adjusted EBITDA
- > Acquired Blueshift Biotechnologies
- > MDS Pharma Services delivered another quarter of strong new business wins, up 42% from prior year

Summary of 2008 Q3 Financial Results (US\$ millions, except EPS, in US GAAP)

	Consolidated			MDS Analytical Technologies			MDS Nordion			MDS Pharma Services		
	Q3 2008	Q3 2007	YOY Growth	Q3 2008	Q3 2007	YOY Growth	Q3 2008	Q3 2007	YOY Growth	Q3 2008	Q3 2007	YOY Growth
Net revenues	\$ 298	\$ 308	(3%)	\$ 104	\$ 114	(9%)	\$ 72	\$ 76	(5%)	\$ 122	\$ 118	3%
Adjusted EBITDA (\$)	\$ 41	\$ 49	(16%)	\$ 21	\$ 27	(22%)	\$ 23	\$ 22	5%	\$ (2)	\$ 4	-
Adjusted EBITDA (%)	14%	16%		20%	24%		32%	29%		(2%)	3%	
Adjusted EPS	\$ 0.06	\$ 0.13		<ul style="list-style-type: none"> • A global leader providing innovative tools for life sciences research and drug discovery and development • Sciex brand offers proven market leadership in mass spectrometry • Molecular Devices brand is the gold standard in high-performance bioanalytical measurement systems 			<ul style="list-style-type: none"> • A global leader in supplying medical isotopes for molecular imaging • Leading provider of sterilization technologies for disease prevention and radiotherapeutics for targeted cancer treatments • A global leader in contract manufacturing for the radiotherapeutics industry 			<ul style="list-style-type: none"> • A global leader in delivering high-quality on-time contract research services at each stage of the drug discovery and development process • Value-added services help to bring new drugs to market safely and efficiently 		
GAAP EPS*	\$ (0.08)	\$ 0.06										
*From continuing operations				Market Size		\$6 billion	Market Size		\$4 billion	Market Size		\$15 billion
				Market Growth		6%–10%	Market Growth		5%–7%	Market Growth		10%–13%

Net Revenue by Business % of 2007



For more information

Investor Relations

Kim Lee
Senior Director,
Investor Relations
(416) 213-4721

Transfer Agent and Registrar

CIBC Mellon Trust Company
Toronto, Ontario, Canada
Telephone: 1 (800) 387-0825
Answer Line: (416) 643-5500

Website

Visit our website www.mdsinc.com for current investor information including news releases, stock quotes, stock charts, annual and interim reports and much more. This information can also be accessed 24 hours a day, seven days a week through the MDS Shareholder Communication Service at 1 (888) MDS-7222.

Analyst Coverage

CIBC World Markets	Maxime Paris
Desjardins Securities	Maher Yaghi
Dundee Securities	David Martin
Goldman Sachs	Randall Stanicky
Jefferies & Company	David Windley
RBC Dominion Securities	Doug Miehme
Scotia Capital	John Maletic
TD Newcrest	Lennox Gibbs